These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 22395469)

  • 1. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells.
    Kim JY; Hwang J; Lee SH; Lee HJ; Jelinek J; Jeong H; Lim JS; Kim JM; Song KS; Kim BH; Lee S; Kim J
    Clin Epigenetics; 2015; 7():99. PubMed ID: 26380584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation.
    Kim JY; Hwang JH; Zhou W; Shin J; Noh SM; Song IS; Kim JY; Lee SH; Kim J
    Epigenetics; 2009 Jul; 4(5):313-21. PubMed ID: 19633424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
    Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
    Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
    Katsura Y; Wada H; Murakami M; Akita H; Hama N; Kawamoto K; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S517-26. PubMed ID: 23508585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
    Schomber T; Zumsteg A; Strittmatter K; Crnic I; Antoniadis H; Littlewood-Evans A; Wood J; Christofori G
    Mol Cancer Ther; 2009 Jan; 8(1):55-63. PubMed ID: 19139113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal Flt1 tyrosine kinase activity is a positive regulator of endothelial survival and vascularization during zebrafish embryogenesis.
    Li S; Zhou XL; Dang YY; Kwan YW; Chan SW; Leung GP; Lee SM; Hoi MP
    Biochim Biophys Acta; 2015 Feb; 1850(2):373-84. PubMed ID: 25450186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation, induced by beta-carotene and arachidonic acid, plays a regulatory role in the pro-angiogenic VEGF-receptor (KDR) gene expression in endothelial cells.
    Kiec-Wilk B; Razny U; Mathers JC; Dembinska-Kiec A
    J Physiol Pharmacol; 2009 Dec; 60(4):49-53. PubMed ID: 20065496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1α and VEGF receptors.
    Mahfouz N; Tahtouh R; Alaaeddine N; El Hajj J; Sarkis R; Hachem R; Raad I; Hilal G
    PLoS One; 2017; 12(6):e0179202. PubMed ID: 28594907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
    Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
    Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
    Wedge SR; Kendrew J; Hennequin LF; Valentine PJ; Barry ST; Brave SR; Smith NR; James NH; Dukes M; Curwen JO; Chester R; Jackson JA; Boffey SJ; Kilburn LL; Barnett S; Richmond GH; Wadsworth PF; Walker M; Bigley AL; Taylor ST; Cooper L; Beck S; Jürgensmeier JM; Ogilvie DJ
    Cancer Res; 2005 May; 65(10):4389-400. PubMed ID: 15899831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
    Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional VEGF and VEGF receptors are expressed in human medulloblastomas.
    Slongo ML; Molena B; Brunati AM; Frasson M; Gardiman M; Carli M; Perilongo G; Rosolen A; Onisto M
    Neuro Oncol; 2007 Oct; 9(4):384-92. PubMed ID: 17704359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
    List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
    Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.